dc.contributor.author |
Otero-Romero, Susana |
|
dc.contributor.author |
Lebrun-Frenay, Christine |
|
dc.contributor.author |
Reyes, Saúl |
|
dc.contributor.author |
Amato, María Pía |
|
dc.contributor.author |
Campins, Magda |
|
dc.contributor.author |
Farez, Mauricio Franco |
|
dc.contributor.author |
Filippi, Massimo |
|
dc.contributor.author |
Hacohen, Yael |
|
dc.contributor.author |
Hemmer, Bernhard |
|
dc.contributor.author |
Juuti, Rosa |
|
dc.contributor.author |
Magyari, Melinda |
|
dc.contributor.author |
Oreja-Guevara, Celia |
|
dc.contributor.author |
Siva, Aksel |
|
dc.contributor.author |
Vukusic, Sandra |
|
dc.contributor.author |
Tintoré, Mar |
|
dc.date.accessioned |
2024-01-04T16:27:28Z |
|
dc.date.available |
2024-01-04T16:27:28Z |
|
dc.date.issued |
2023-06-09 |
|
dc.identifier.citation |
Otero-Romero S, Lebrun-Frenay C, Reyes S, Amato MP, Campins M, Farez M, Filippi M, Hacohen Y, Hemmer B, Juuti R, Magyari M, Oreja-Guevara C, Siva A, Vukusic S, Tintoré M. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043 |
es_ES |
dc.identifier.uri |
https://doi.org/10.1177/13524585231168043 |
|
dc.identifier.uri |
https://repositorio.fleni.org.ar/xmlui/handle/123456789/955 |
|
dc.description.abstract |
Background: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy.
Objective: To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs).
Methods: This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk-benefit balance.
Results: Seven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in sub-populations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines, and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus.
Conclusion: This first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS. |
es_ES |
dc.language.iso |
eng |
es_ES |
dc.publisher |
Sage |
es_ES |
dc.rights |
info:eu-repo/semantics/openAccess |
|
dc.subject |
Multiple Sclerosis |
es_ES |
dc.subject |
Esclerosis Múltiple |
es_ES |
dc.subject |
Pregnancy |
es_ES |
dc.subject |
Embarazo |
es_ES |
dc.subject |
Vaccination |
es_ES |
dc.subject |
Vacunación |
es_ES |
dc.subject |
Evidence-Based Medicine |
es_ES |
dc.subject |
Medicina Basada en la Evidencia |
es_ES |
dc.title |
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs |
es_ES |
dc.type |
info:eu-repo/semantics/article |
es_ES |
dc.type |
info:eu-repo/semantics/publishedVersion |
|
dc.description.fil |
Fil: Farez, Mauricio Franco. Fleni. Centro para la Investigación de Enfermedades Neuroinmunológicas; Argentina. |
|
dc.relation.ispartofVOLUME |
29 |
|
dc.relation.ispartofNUMBER |
8 |
|
dc.relation.ispartofPAGINATION |
904-925 |
|
dc.relation.ispartofCOUNTRY |
Reino Unido |
|
dc.relation.ispartofCITY |
Londres |
|
dc.relation.ispartofTITLE |
Multiple sclerosis |
|
dc.relation.ispartofISSN |
1477-0970 |
|
dc.type.snrd |
info:ar-repo/semantics/artículo |
es_ES |